A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003) - Full Text View

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00886613

Purpose

A study in two parts (Part A and Part B) to evaluate the responsiveness of various biomarkers of immunity to Varicella-Zoster Virus (VZV) following repeated immunizations with heat treated VZV vaccine V212 or with Zostavax™.

The enrollment of participants into this study was conducted in 2 parts, Part A and Part B. The first 42 eligible participants were enrolled into Part A of the study. In Part A, the reaction of the VZV skin test at baseline was evaluated at both 48 and 72 hours post administration of the VZV skin test reagent and saline (in opposite arms), with 2 examiners performing the reading at each timepoint; all subsequent skin test readings in Part A were performed at 48 hours post administration. After all skin test reactions were obtained at baseline for the 42 subjects in Part A, an interim analysis was performed (1) to assess the frequency of baseline negative skin tests in order to confirm that the planned sample size (N=120) was adequate for an evaluation of the effect of vaccination on the VZV Skin Test, and (2) to assess the frequency of baseline positive skin tests at 72 hours relative to 48 hours (post administration) in order to determine the preferred time for evaluation of the skin test reaction.

The interim analysis from Part A confirmed the study sample size, an additional 78 subjects were enrolled into Part B to achieve the planned sample size (N=120). The study procedures for Part B of the study were identical to those in Part A with the following exceptions: (1) baseline skin test readings were performed only once, at either 48 or 72 hours (post administration) to accommodate the scheduling of clinic visits, and (2) only one examiner was needed for the skin test reading at baseline.

Condition	Intervention	Phase
Herpes Zoster	Biological: V212 Biological: Comparator: Zostavax™ Biological: Comparator: Placebo Other: VZV Skin Test Other: Saline	Phase I

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention
Official Title:	A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate Biomarkers of Immunity to Varicella Zoster Virus Following Immunization With V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine or With ZOSTAVAX in Healthy Volunteers

Resource links provided by NLM:

MedlinePlus related topics: Chickenpox Shingles

Drug Information available for: Zostavax

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

Number of Participants With a Negative VZV Skin Test at Baseline (Part A) [ Time Frame: 48 hours following administration of the baseline skin test ] [ Designated as safety issue: No ]
Participants were given the VZV skin test prior to vaccination. For the baseline VZV skin test, they were administered VZV skin test reagent and saline in opposite arms, and assessed for a skin reaction around the injection site. The skin reaction assessed was erythema (redness of skin) and induration (palpable, raised, hardened area) around the injection site, which was marked with a ball point pen. The longest dimension to the closest 1 mm was measured. Participants with a reaction measure < 5mm for saline and < 5mm for the VZV antigen were considered to have a negative baseline skin test.
Number of Healthy, Elderly, Immunocompetent Participants With a Positive VZV Skin Test After Administration of 2 Doses of V212 Vaccine (Part B) [ Time Frame: 48-72 hours after administration of skin test at 14-17 days postdose 2 ] [ Designated as safety issue: No ]
Number of participants with a positive VZV skin test after 2 vaccine doses was determined. Participants with a negative VZV skin test reaction at baseline were evaluated for VZV immunogenicity by a final VZV skin test administered 14 days after dose 2 of vaccination.

For the VZV skin test participants were injected intradermally with the VZV skin test reagent, and reaction to the skin test was assessed after 48-72 hrs. A skin reaction (erythema and induration) around the injection site measuring >= 5mm for the VZV antigen was considered a positive skin test.

Secondary Outcome Measures:

VZV Skin Test Reactions at 48 and 72 Hours (Part A) [ Time Frame: 48 hours and 72 hours post administration of baseline skin test ] [ Designated as safety issue: No ]
Prior to vaccination, participants were administered a baseline VZV skin test for which the skin test reagent and saline were injected in opposite arms. The skin reaction (erythema and induration) around the injection site was assessed at 48 hours and at 72 hours. The reaction was marked with a ball point pen and the longest dimension closest to 1 mm was measured. Participants with a reaction measure < 5mm for saline and < 5mm for the VZV antigen were defined as having a negative baseline skin test; and a measure of >= 5mm for the VZV antigen were defined as having a positive skin test.
Number of Healthy Elderly Men and Women With Adverse Events Post Vaccination With V212 (Part B) [ Time Frame: 1-28 days post vaccination dose 1 and 1-28 days post vaccination dose 2 ] [ Designated as safety issue: Yes ]
The number of participants with all serious and nonserious adverse events, and vaccine-related serious and nonserious adverse events, from 1-28 days post any vaccination dose was determined to assess safety. Non serious adverse events include injection-site adverse events as well as systemic adverse events post vaccination. Vaccine-related events include all events that were possibly, probably or definitely related to the vaccine according to the investigator. Participants with injection site adverse events due to administration of VZV skin tests are not included.
Number of Healthy Elderly Men and Women With Injection Site Adverse Events Post Administration of VZV Skin Tests (Part B) [ Time Frame: 1-5 days post administration of each VZV skin test ] [ Designated as safety issue: Yes ]
The number of participants with injection site adverse events due to the VZV skin test after administration of the VZV skin test antigen.

Enrollment:	120
Study Start Date:	March 2009
Study Completion Date:	December 2009
Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: V212 Participants randomized to receive V212 (heat treated VZV Vaccine)	Biological: V212 Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31 Other Name: V212 Other: VZV Skin Test Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination. Other: Saline One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
Active Comparator: Zostavax™ Participants randomized to receive Zostavax™ (Zoster Vaccine, live)	Biological: Comparator: Zostavax™ Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31 Other Name: V211 (Zoster Vaccine Live (Oka/Merck)) Other: VZV Skin Test Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination. Other: Saline One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
Placebo Comparator: Placebo Participants randomized to receive placebo	Biological: Comparator: Placebo Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31 Other: VZV Skin Test Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination. Other: Saline One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.

Detailed Description:

All eligible participants, regardless of treatment group, were administered three injections of the varicella antigen (VZV Skin Test reagent), once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination. Reactions to the skin test were assessed by the same examiner for each participant to the greatest extent possible.

Eligibility

Ages Eligible for Study:	60 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Participant has prior history of Varicella
Female participants are of non-childbearing potential

Exclusion Criteria:

Participant has had a hypersensitivity reaction to any vaccine component
Participant has a prior history of Herpes Zoster
Participant has received any Varicella or Zoster vaccine including Zostavax
Participant has a history of immunosuppression caused by disease, corticosteroids, cancer therapy or organ transplant
Participant has an active cancer
Participant has received or will receive a live virus vaccine or an inactivated virus vaccine 4 weeks prior to participating in study (with the exception of influenza vaccine)
Participant is not bed-ridden or homebound

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00886613

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

Responsible Party:	Vice President, Late Stage Development Group Leader, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier:	NCT00886613 History of Changes
Other Study ID Numbers:	V212-003, 2009_579
Study First Received:	April 22, 2009
Results First Received:	March 22, 2011
Last Updated:	May 3, 2011
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Chickenpox
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on February 09, 2012